Meanwhile a U.S. biotech company has announced a potential treatment for coronavirus. The drug, first developed to fight Ebola, has shown some promise in treating a patient in America. Further clinical trials are being carried out in China right now. The leader of the team behind the drug is a Taiwanese woman. On Twitter, American biotech company Gilead Sciences announced they may have a breakthrough on coronavirus treatment.According to a report in the New England Journal of Medicine, a coronavirus patient in the U.S. was given the antiviral Remdesivir 11 days after symptoms began. The next day, many symptoms improved: their appetite returned and their cough and runny nose turned around. The leader of the research team behind the drug is Taiwanese.Yang Taiyin is the executive vice president of pharmaceutical development and manufacturing at Gilead. She received her bachelor''s in chemistry from National Taiwan University and her Ph.D. from the University of Southern California, before joining Gilead in 1993. She rose to her current position in 2015, the same year she announced the antiviral drug Remdesivir. It was originally developed as a treatment for Ebola, later deemed relatively ineffective and dropped. But now it’s found a potential new use treating coronavirus.Chen Shih-chungCentral Epidemic Command CenterConcerning Gilead’s new drug, of course it must go through trials to prove its efficacy, like any new drug. But as part of our current work we are in talks with Gilead, and they’re going to reserve a stock of the drug for Taiwan.Taiwanese officials are liaising with the company and plan to carry out more tests. There are three drugs believed by scientists to have some potential in treating coronavirus.Researchers at Beijing’s Capital Medical University say that Lopinavir/ritonavir, a drug combination used to treat HIV/AIDS, could work. A doctor in Thailand combined them with anti-flu drugs to treat a patient, whose condition improved within 48 hours. But all these potential treatments need further clinical trials before they can be rolled out.
Meanwhile a U.S. biotech company has announced a potential treatment for coronavirus. The drug, first developed to fight Ebola, has shown some promise in treating a patient in America. Further clinical trials are being carried out in China right now. The leader of the team behind the drug is a Taiwanese woman. On Twitter, American biotech company Gilead Sciences announced they may have a breakthrough on coronavirus treatment.According to a report in the New England Journal of Medicine, a coronavirus patient in the U.S. was given the antiviral Remdesivir 11 days after symptoms began. The next day, many symptoms improved: their appetite returned and their cough and runny nose turned around. The leader of the research team behind the drug is Taiwanese.Yang Taiyin is the executive vice president of pharmaceutical development and manufacturing at Gilead. She received her bachelor''s in chemistry from National Taiwan University and her Ph.D. from the University of Southern California, before joining Gilead in 1993. She rose to her current position in 2015, the same year she announced the antiviral drug Remdesivir. It was originally developed as a treatment for Ebola, later deemed relatively ineffective and dropped. But now it’s found a potential new use treating coronavirus.Chen Shih-chungCentral Epidemic Command CenterConcerning Gilead’s new drug, of course it must go through trials to prove its efficacy, like any new drug. But as part of our current work we are in talks with Gilead, and they’re going to reserve a stock of the drug for Taiwan.Taiwanese officials are liaising with the company and plan to carry out more tests. There are three drugs believed by scientists to have some potential in treating coronavirus.Researchers at Beijing’s Capital Medical University say that Lopinavir/ritonavir, a drug combination used to treat HIV/AIDS, could work. A doctor in Thailand combined them with anti-flu drugs to treat a patient, whose condition improved within 48 hours. But all these potential treatments need further clinical trials before they can be rolled out.
0 Comments